enow.com Web Search

  1. Ads

    related to: oral treatments for plaque psoriasis

Search results

  1. Results from the WOW.Com Content Network
  2. Deucravacitinib - Wikipedia

    en.wikipedia.org/wiki/Deucravacitinib

    Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. [7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. [7] It was developed by Bristol Myers Squibb. [10]

  3. Psoriasis - Wikipedia

    en.wikipedia.org/wiki/Psoriasis

    Psoriasis vulgaris (also known as chronic stationary psoriasis or plaque-like psoriasis) is the most common form and affects 85–90% of people with psoriasis. [13] Plaque psoriasis typically appears as raised areas of inflamed skin covered with silvery-white, scaly skin. These areas are called plaques and are most commonly found on the elbows ...

  4. Bimekizumab - Wikipedia

    en.wikipedia.org/wiki/Bimekizumab

    Bimekizumab, sold under the brand name Bimzelx (/ b ɪ m ˈ z ɛ l ɪ k s / bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody [6] [7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.

  5. 7 Proven Treatments for Plaque Psoriasis - AOL

    www.aol.com/lifestyle/7-proven-treatments-plaque...

    Reader's DigestHome Remedies for Eczema and Psoriasis ReliefSave money on expensive skin care treatments and try these homemade remedies first. Plaque psoriasis is a skin disease that causes ...

  6. Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque ...

    www.aol.com/news/bristol-myers-deucravacitinib...

    The FDA approved Bristol Myers Squibb Co's (NYSE: BMY) Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for ...

  7. Apremilast - Wikipedia

    en.wikipedia.org/wiki/Apremilast

    Apremilast was approved by the US Food and Drug Administration (FDA) in 2014, for treatment of adults with active psoriatic arthritis and moderate to severe plaque psoriasis, and approved in 2019, for oral ulcers associated with Behçet's disease. [21] [22] [23] Apremilast is taken by mouth. [24]

  1. Ads

    related to: oral treatments for plaque psoriasis